COSMOS Pharmaceutical Corporation

TSE:3349.T

7338 (JPY) • At close January 14, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Revenue 964,989827,697755,414726,424684,403611,137557,999502,732447,273408,466371,825329,313279,021237,174205,387177,756148,244125,846105,04678,651
Cost of Revenue 776,683658,979603,966581,313549,419489,353447,681402,688360,420330,391301,268267,527226,035191,672165,323141,741115,54797,49181,76160,937
Gross Profit 188,306168,718151,448145,111134,984121,784110,318100,04486,85378,07570,55761,78652,98645,50240,06436,01532,69728,35523,28517,714
Gross Profit Ratio 0.1950.2040.20.20.1970.1990.1980.1990.1940.1910.190.1880.190.1920.1950.2030.2210.2250.2220.225
Reseach & Development Expenses 00000000000000000000
General & Administrative Expenses 11612812712912712812911811711611912700003,9784,6033,8793,106
Selling & Marketing Expenses 1,8121,6481,6322,7844,2663,7711,8361,8151,6881,7811,6451,29700001,224929896764
SG&A 138,536122,807107,75699,16393,34785,05076,68068,09759,44254,09548,51742,08700005,2025,5324,7753,870
Other Expenses 18,2692,9603,0662,7412,5462,5212,5152,3662,0431,6151,4381,2121,1601,0371,095802688652476291
Operating Expenses 156,805138,589121,651111,964105,89097,00887,56877,80668,20560,99353,84946,25639,65735,46232,32130,57627,88924,59219,87715,455
Operating Income 31,50130,12829,79633,14729,09424,77522,74922,23718,64817,08016,70715,52913,32910,0407,7435,4394,8083,7633,4082,259
Operating Income Ratio 0.0330.0360.0390.0460.0430.0410.0410.0440.0420.0420.0450.0470.0480.0420.0380.0310.0320.030.0320.029
Total Other Income Expenses Net 2,2182,6453,2525,4491,3082,3642,4183,5001,8482,3401,7091,1231,0695291,012-113-677558311143
Income Before Tax 33,71932,77333,04838,59630,40227,13925,16725,73720,49619,42018,41616,65214,39810,5698,7555,3264,1314,3213,7192,402
Income Before Tax Ratio 0.0350.040.0440.0530.0440.0440.0450.0510.0460.0480.050.0510.0520.0450.0430.030.0280.0340.0350.031
Income Tax Expense 9,2658,9759,89211,4398,9677,9547,5347,5228,0617,7257,8157,2556,6614,8314,0432,4841,9572,0211,7751,142
Net Income 24,45423,79723,15527,15621,43519,18517,63318,21512,43511,69410,6009,3967,7375,7374,7122,8412,1732,2991,9441,259
Net Income Ratio 0.0250.0290.0310.0370.0310.0310.0320.0360.0280.0290.0290.0290.0280.0240.0230.0160.0150.0180.0190.016
EPS 308.61300.48292.37342.89270.65242.24222.64229.99157.01147.65133.84237.28195.39144.911971.7654.4957.4851.0374.79
EPS Diluted 308.61300.48292.37342.89270.65242.24222.64229.99157.01147.65133.84237.28195.39144.911971.7654.4957.4851.0374.79
EBITDA 53,74447,49744,90746,93242,65637,73434,63532,94828,23624,42422,31220,95617,58313,04710,7536,8785,2765,2664,4412,936
EBITDA Ratio 0.0560.0610.0640.0680.0660.0660.0670.070.0680.0650.0640.0640.0630.0570.0530.0440.0450.0420.0430.038